Clinical Trials

Title   Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer
Description   This dose escalation study will determine a maximum tolerated dose and/or optimal biological dose of GEN-1 for carboplatin/paclitaxel combination in newly diagnosed ovarian cancer.
IRB Number   18-158
Treatment   Oncology - Ovarian Cancer
Status   Active
Start Date   05/08/2018
Principal Name   Rodney Rocconi, MD
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us